XCR1 and neoplasm: Unexpected, we did not observe significant XCR1 RO (Figure 5B), or a gain in IFN activity in cDC1-targeted cells in the spleen or tumor (Figure 5C), following 3 injections with the XCR1Ab-IFNL53A fusion.